Investigational New Drugs

, Volume 19, Issue 3, pp 245–247

Phase II Study of Bryostatin 1 in Patients with Relapsed Multiple Myeloma

Authors

  • Mary L. Varterasian
    • Karmanos Cancer InstituteWayne State University
  • Pamela A. Pemberton
    • Karmanos Cancer InstituteWayne State University
  • Kim Hulburd
    • Karmanos Cancer InstituteWayne State University
  • Dorothy H. Rodriguez
    • Karmanos Cancer InstituteWayne State University
  • Anthony Murgo
    • Investigational Drug BranchCTEP, DCTDC, NCI
  • Ayad M. Al-Katib
    • Karmanos Cancer InstituteWayne State University
Article

DOI: 10.1023/A:1010676719178

Cite this article as:
Varterasian, M.L., Pemberton, P.A., Hulburd, K. et al. Invest New Drugs (2001) 19: 245. doi:10.1023/A:1010676719178

Abstract

Bryostatin 1, a macrocyclic lactoneisolated from the marine bryozoan Bugula neritina,is a protein kinase C (PKC) modulator which has shown bothpreclinical and clinical activity inlymphoid malignancies. We conducted aphase II trial of bryostatin 1 administeredat a dose of 120 μg/m2 by 72-hcontinuous infusion every 2 weeks inpatients with relapsed multiple myeloma. Treatment was well tolerated with myalgiasconstituting the primaray toxicity. Therewere no responses in nine evaluablepatients. The preclinical anti-lymphoidactivity is strong enough to supportfurther exploration of bryostatin 1 indifferent schedules and in combinationtherapy for multiple myeloma.

Phase IIbryostatin 1multiple myelomarelapsed
Download to read the full article text

Copyright information

© Kluwer Academic Publishers 2001